Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Chondrosarcoma 2Sinonasal undifferentiated carcinoma 1Immunoblastic Lymphadenopathy 1Glioma 1Esthesioneuroblastoma, Olfactory 1Cholangiocarcinoma 1

Interventions

Nivolumab 3Quality of Life 2Magnetic Resonance Spectroscopy 2Gemcitabine 2Fluorodeoxyglucose F18 2Drug Therapy 2Cisplatin 2trametinib 1tislelizumab 1spartalizumab 1seribantumab 1pembrolizumab 1pazopanib 1milademetan 1ivosidenib 1entrectinib 1enasidenib 1durvalumab 1crenigacestat 1apixaban 1alectinib 1abemaciclib 1Surveys and Questionnaires 1Specimen Handling 1Rivaroxaban 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Metformin 1LY3023414 1LY2940680 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × enasidenib × Sarcoma × Clear all
NCT02273739 2021-02-23

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Celgene

Phase 1/2 Completed
21 enrolled 33 charts
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Immunoblastic Lymphadenopathy, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡